BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.

A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

Speculation about the alleged findings of a study on long COVID and post-vaccination syndrome spread widely among vaccine ...

Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...

Most people now have some degree of immunity to COVID, either from vaccination or infection, Schaffner said. The data on how ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...